**List of publications:**

**Research Papers**

1. S Moulik, J Karmakar, S Joshi, **A Dube**, C Mandal, M Chatterjee (2020). Status of IL-4 and IL-10 driven markers in experimental models of Visceral Leishmaniasis. *Parasite Immunol*. Jul 31: e12783. doi: 10.1111/pim.12783. Epub ahead of print. PMID: 32734677.
2. S Saini, SK Kottarath, AK Dinda, **A Dube**, AA Sahasrabuddhe, CP Thakur, M Bhat, AK Rai (2020). Preventive as well as therapeutic significances of linoleic acid in the containment of *Leishmania donovani* infection. *Biochimie*. Aug; **175**:13-22. doi: 10.1016/j.biochi.2020.04.024. Epub 2020 May 18. PMID: 32439363.
3. P Misra, R Tandon, T Basak, S Sengupta, **A Dube** (2020). Purified Splenic amastigotes of Leishmania donovani-Immunoproteomic approach for exploring Th1 stimulatory polyproteins. *Parasite Immunol*. Nov; **42** (11): e12729. doi: 10.1111/pim.12729. Epub ahead of print. PMID: 32415855.
4. S Saini, B Singh, S Prakash, S Kumari, AK Kureel, **A Dube**, AA Sahasrabuddhe, AK Rai (2020). Parasitic load determination by differential expressions of 5-lipoxygenase and PGE2 synthases in visceral leishmaniasis*. Prostaglandins Other Lipid Mediat.* Apr;**147**: 106390. doi: 10.1016/j.prostaglandins.2019.106390. Epub 2019 Nov 11. PMID: 31726220.
5. S Saini, **A Dube**, AA Sahasrabuddhe, CP Thakur, S Joshi, K Rawat, AK Rai (2020). Comparison Between Immuno-Clinicopathological Features of Experimental and Human Visceral Leishmaniasis by *Leishmania donovani*. *Acta Parasitol*. Mar;**65** (1): 57-67. doi: 10.2478/s11686-019-00127-8. Epub 2019 Oct 1. PMID: 31578670.
6. S Joshi, NK Yadav, K Rawat, V Kumar, R Ali, AA Sahasrabuddhe, MI Siddiqi, W Haq, S Sundar, **A Dube** (2019). Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived from Potential Th1 Stimulatory Proteins of Leishmania (Leishmania) donovani. *Front Immunol*. 10: 288. doi: 10.3389/fimmu.2019.00288. eCollection 2019.PMID: 30873164
7. P Kumar, P Misra, NK Yadav, S Joshi, AA Sahasrabuddhe, **A Dube**, N Rishi, DK Mitra (2019). Prophylactic interferon-γ and interleukin-17 facilitate parasite clearance in experimental visceral leishmaniasis. *Trop Parasitol*. 9 :30-35. DOI: [10.4103/tp.TP\_32\_18](https://doi.org/10.4103/tp.tp_32_18) PMID: 31161090
8. R Tandon, S Chandra, RK Baharia, S Das, Ki Rawat, P Misra, MI Siddiqi and **A Dube** (2018) "Molecular, biochemical characterization and assessment of immunogenic potential of Cofactor-independent phosphoglycerate mutase against *Leishmania donovani*: A step towards exploring novel vaccine candidate” *Parasitology* 145: 508-526. doi: 10.1017/S0031182017001160. Epub 2017 Jul 10. PMID: 28691653
9. PK Singh, AK Jaiswal, VK Pawar, K Raval, A Kumar, HK Bora, **A Dube**, MK Chourasia (2018). Fabrication of 3-O-sn-Phosphatidyl-L-serine Anchored PLGA Nanoparticle Bearing Amphotericin B for Macrophage Targeting. *Pharm Res*. Feb 9;35 (3):60. doi: 10.1007/s11095-017-2293-1. PubMed PMID: 29427248.
10. UL Kariyawasam, A Selvapandiyan, YD Siriwardana, **A Dube**, P Karunanayake, SC Senanayake, R Dey, S Gannavaram, HL Nakhasi, ND Karunaweera (2018) Dermotropic *Leishmania donovani* in Sri Lanka: visceralizing potential in clinical and preclinical studies. *Parasitology*. 145(4):443-452. doi: 10.1017/S003118201700169X. Epub 2017 Nov 8. PMID: 29113609
11. K Rawat, NK Yadav, S Joshi, S Ratnapriya, AA Sahasrabuddhe, **A Dube** (2018) Immunotherapeutic potential of *Leishmania (Leishmania) donovani* Th1 stimulatory proteins against experimental visceral leishmaniasis. *Vaccine.* Apr 19; **36** (17):2293-2299.  doi: 10.1016/j.vaccine.2018.03.027. Epub 2018 Mar 21.PMID: 29573875
12. P Tripathi, AK Jaiswal, **A Dube**, PR Mishra (2017) Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of *Leishmania donovani*. *Int J Biol Macromol*. 105 (Pt 1):625-637. doi: 10.1016/j.ijbiomac.2017.07.076. Epub 2017 Jul 15.PMID: 28716750
13. AK Sinha, P Singh, A Prakash, D Pal, **A Dube**, A Kumar (2017) Putative Drug and Vaccine Target Identification in Leishmania donovani Membrane Proteins Using Naïve Bayes Probabilistic Classifier. *IEEE/ACM Trans Comput Biol Bioinform*. 14:204-211. doi: 10.1109/TCBB.2016.2570217.PMID: 28182549
14. UL Kariyawasam, YD Siriwardena, **A Dube**, HL Nakhasi, ND Karunaweera (2017) The Role of IL‐10 and IFN‐Gamma in virulence of Dermotropic Leishmania donovani in Sri Lanka. *Reviews in Aquaculture*. 95 (5) 550-551.
15. PK Singh, VK Pawar, AK Jaiswal, Y Singh, CH Srikanth, M Chaurasia, HK Bora, K Raval, JG Meher, JR Gayen, **A Dube**, MK Chourasia (2017) Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis. *Int J Biol Macromol*. 105(Pt1):1220-1231. doi: 10.1016/j.ijbiomac.2017.07.161. Epub 2017 Aug 3. PMID: 28780414
16. CD Tripathi, PK Kushawaha, RS Sangwan, C Mandal, S Misra-Bhattacharya, **A Dube** (2017) Withania somnifera chemotype NMITLI 101R significantly increases the efficacy of antileishmanial drugs by generating strong IFN-γ and IL-12 mediated immune responses in *Leishmania donovani* infected hamsters. *Phytomedicine*. 24: 87-95. doi: 10.1016/j.phymed.2016.11.012. Epub 2016 Nov 16. PMID: 28160866
17. PK Singh, P Sah, JG Meher, S Joshi, VK Pawar, K Raval, Y Singh, K Sharma, A Kumar, **A Dube** and MK Chourasia. (2016) Macrophage-targeted chitosan anchored PLGA nanoparticles bearing doxorubicin and amphotericin B against visceral leishmaniasis. *RSC ADVANCES*, 6, 75: 71705-71718
18. M Chaurasia, PK Singh, AK Jaiswal, A Kumar, VK Pawar, **A Dube**, SK Paliwal, MK Chourasia (2016) Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis. *Pharm Res*. 33: 2617-29. doi: 10.1007/s11095-016-1985-2. Epub 2016 Jul 11. PMID: 27401407
19. AK Jaiswal; KB Rao; P Kushwaha; K Rawat; RK Modukuri; P Khare; S Joshi; S Mishra; A Rai; KV Sashidhara; **A Dube** (2016) Development of stably expressed DsRed Leishmania donovani for flow cytometric based drug screening using chalconethiazolyl-hydrazone as a new antileishmanial target. *International Journal of Antimicrobial Agents* 48 (6):695-702. doi: 10.1016/j.ijantimicag.2016.09.018. Epub 2016 Nov 2. PMID: 27876275
20. S Joshi, NK Yadav, K Rawat, CP Tripathi, AK Jaiswal, P Khare, R Tandon, RK Baharia, S Das, R Gupta, PK Kushawaha, S Sundar, AA Sahasrabuddhe, **A Dube** (2016) Comparative analysis of cellular immune responses in treated Leishmania patients and hamsters against recombinant Th1 stimulatory proteins of Leishmania donovani. *Frontiers in Microbiology* 22:7:312. doi: 10.3389/fmicb.2016.00312. eCollection 2016.PMID: 27047452
21. SK Pandya, R Verma, P Khare, B Tiwari, DA Srinivasarao, **A Dube**, N Goyal, A Misra (2016) Supplementation of host response by targeting nitric oxide to the macrophage cytosol is efficacious in the hamster model of visceral leishmaniasis and adds to efficacy of Amphotericin B. *International Journal for Parasitology: Drugs and Drug Resistance* 14;6(2):125-132. doi: 10.1016/j.ijpddr.2016.01.001. Epub 2016 Jan 14. PMID: 27183429
22. P Khare, AK Jaiswal, CD Tripathi, S Sundar, **A Dube** (2016). Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis. *Clin Exp Immunol*. Aug;185 (2):165-79. doi: 10.1111/cei.12780. Epub 2016 Apr 27. PMID: 26898994; PMCID: PMC4954996
23. M Chaurasia, VK Pawar, AK Jaiswal, **A Dube**, SK Paliwal, MK Chourasia (2015) Chondroitin nanocapsules enhanced doxorubicin induced apoptosis against leishmaniasis via th1 immune response. *International Journal of Biological Macromolecules* 79: 27-36. doi: 10.1016/j.ijbiomac.2015.04.043. Epub 2015 Apr 27. PMID: 25931395
24. S Asthana, PK Gupta, AK Jaiswal, **A Dube**, MK Chourasia (2015) Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipidpolymer hybridnanoparticle: biodistribution and toxicity assessment of encapsulated Amphotericin B. *European Journal of Pharmaceutics and Biopharmaceutics* 89: 62-73. doi: 10.1016/ j.ejpb.2014.11.019. Epub 2014 Dec 1. PMID: 25477079
25. S Asthana, PK Gupta, AK Jaiswal, **A Dube**, MK Chourasia (2015) Overexpressed macrophage mannose receptor targeted nanocapsules- mediated cargo delivery approach for eradication of resident parasite: *in vitro* and *in vivo* studies. *Pharmaceutical Researc*h 32(8): 2663-2677. doi: 10.1007/s11095-015-1651-0. Epub 2015 Feb 27. PMID: 25715698
26. S Das, P Shah, R Tandon, NK Yadav, AA Sahasrabuddhe, S Sundar, MI Siddiqi, **A Dube** (2015) Over-Expression of Cysteine Leucine Rich Protein Is Related to SAG Resistance in Clinical Isolates of *Leishmania donovani*. *PLoS Negl. Trop. Dis*. Aug 21;9(8): e0003992. doi: 10.1371/journal.pntd.0003992. eCollection 2015 Aug.PMID: 26295340
27. P Tripathi, P Dwivedi, R Khatik, AK Jaiswal, **A Dube**, P Shukla, PR Mishra (2015) Development of 4-sulfated N-acetyl galactosamine anchored chitosan nanoparticles: A dual strategy for effective management of Leishmaniasis. *Colloids Surf B Biointerfaces*. 136:150-159. doi: 10.1016/j.colsurfb.2015.08.037. Epub 2015 Aug 24. PMID: 26381698
28. PK Gupta, AK Jaiswal, S Asthana, BV Teja, P Shukla, M Shukla, N Sagar, **A Dube**, SK Rath, PR Mishra (2015) Synergistic enhancement of the parasiticidal activity of Amphotericin B using copaiba oil in nano-emulsified carrier for oral delivery: An approach for nontoxic chemotherapy. *British Journal of Pharmacology* 172(14):3596-3610. doi: 10.1111/bph.13149. Epub 2015 May 19. PMID: 25825339
29. A Kumar, M Samant, P Misra, P Khare, S Sundar, **A Dube** (2015) Immunostimulatory potential and proteome profiling of *Leishmania donovani* soluble exogenous antigens. *Parasite Immunology* 37:368-375. doi: 10.1111/pim.12189.PMID: 25824598
30. P Gupta, AK Jaiswal, S Asthana, A Verma, P Shukla, P Dwivedi, **A Dube**, PR Mishra (2015) Self assembled ionically sodium alginate cross-linked Amphotericin B encapsulated glycol chitosan stearate nanoparticles: Applicability in better chemotherapy and non-toxic delivery of AmB in visceral leishmaniasis *Pharmaceutical Research* 32(5):1727-1740.doi:10.1007 /s11095-014-1571-4. Epub 2014 Nov 26. PMID: 25425053
31. S Asthana, PK Gupta, AK Jaiswal, **A Dube**, MK Chourasia (2015) Targeted chemotherapy of visceral leishmaniasis by lactoferrin appended Amphotericin B loaded nano-reservoir in vitro and *in vivo* studies. *Nanomedicine* 10 (7) :1093-1109. doi: 10.2217/nnm.14.182. PMID:25929567
32. V Lakshmi, P Khare, P Misra, MN Srivastava, **A Dube** (2015) Antileishmanial potential of a marine sponge *Haliclona oculata* against experimental Visceral Leishmaniasis. *Journal of Coastal Life Medicine* 3 (3): 187-192. doi: 10.12980/JCLM.3.2015APJTB-2014-0087
33. RK Baharia, R Tandon, T Sharma, MK Suthar, S Das, MI Siddiqi, JK Saxena, S Sunder, **A Dube** (2015) Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: Immuno-biochemical characterization as a potential vaccine against Visceral leishmaniasis. *PLoS NTD*. Mar 6;9(3): e0003557. doi:10.1371/journal.pntd.0003742. eCollection 2015 Apr. PMID: 25901962
34. A Kumar, P Misra, B Sisodia, AK Shasany, S Sundar, **A Dube** (2015) Proteomic analyses of membrane enriched proteins of Leishmania donovani Indian clinical isolate by mass spectrometry. *Parasitology International* 15;64(4):36-42. doi: 10.1016/j.parint.2015.01.004. Epub 2015 Jan 15. PMID: 25597695
35. PK Gupta, AK Jaiswal, S Asthana, **A Dube**, PR Mishra (2015) Antigen presenting cells targeting and stimulation potential of lipoteichoic acid functioned Lipo-polymerosome: A chemo-immunotherapeutic approach against intracellular infectious disease. *Biomacromolecules* 16 (4):1073-1087. doi: 10.1021/bm5015156. Epub 2015 Feb 27. PMID: 25671728
36. AK Jaiswal, P Khare, S Joshi, K Rawat, NK Yadav, S Sundar, **A Dube** (2015) Immunological consequences of stress related proteins - Cytosolic Tryparedoxin Peroxidase and Chaperonin TCP20, identified in splenic amastigotes of *Leishmania donovani* as Th1 stimulatory, in experimental visceral leishmaniasis. *Parasitology* 142 (5):728-744. doi: 10.1017/S003118201400184X. Epub 2014 Dec 11. PMID: 25498563
37. V Lakshmi, P Khare, P Misra, MN Srivastava, **A Dube** (2014) Antileishmanial potential of *Chondrococcus hornemanii* against experimental visceral leishmaniasis. *J Mar Biol Oceanogr* 3 4, 2. DOI: [10.4172/2324-8661.1000137](https://www.researchgate.net/deref/http%3A%2F%2Fdx.doi.org%2F10.4172%2F2324-8661.1000137?_sg%5B0%5D=GvDf-6ZqyBD9kZebV2xZrgj9h10EwDn4pczd8uA-VLE41-6mZJoVun7cu4i4JHUSf2A1IKsSGE2gL6sDbe2VZThgJA.qXxhHT8fkDmRgh5uVWGV1LJXPDHk7rqpxVAOA50Xte-BNscKU7vzSHweIMH4zlFlNDSjRJ5pFQFvg4-azmjMDw)
38. AK Jaiswal, P Khare, S Joshi, PK Kushawaha, S Sundar, **A Dube** (2014) Th1 stimulatory proteins of *Leishmania donovani*: Comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. *PLoS One* 9: e108556. doi: 10.1371/journal.pone.0108556. eCollection 2014.PMID: 25268700
39. V Jain, A Gupta, VK Pawar, S Asthana, AK Jaiswal, **A Dube**, MK Chourasia (2014) Chitosan-Assisted Immunotherapy for Intervention of Experimental Leishmaniasis via Amphotericin B-Loaded Solid Lipid Nanoparticles. *Appl Biochem Biotechnol*. 174(4):1309-1330. doi: 10.1007/s12010-014-1084-y. Epub 2014 Aug 9.PMID: 25106894
40. P Khare, P Rastogi, S Gupta, R Maurya, **A Dube** (2014) *In vitro* and *In vivo* Efficacy of a New Herbaceous Indian Plant- Abutilon indicum against *Leishmania donovani* Infection. *American Journal of Phytomedicine and Clinical Therapeutics* 2 Jan 134-139.
41. RK Baharia, R Tandon, AA Sahasrabuddhe, S Sundar, **A Dube** (2014) Nucleosomal Histone Proteins of *Leishmania donovani*: A combination of Recombinant H2A, H2B, H3 and H4 Proteins were highly immunogenic and offered optimum prophylactic efficacy against Leishmania challenge in hamsters. *PLoS One* 9: e97911. doi: 10.1371/journal.pone.0097911. eCollection 2014.PMID: 24926878
42. R Khatik, P Dwivedi, P Khare, S Kansal, A Dube, PR Mishra, AK Dwivedi (2014) Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved *in vitro* and *in vivo* effect in leishmaniasis. *Expert Opin Drug Deliv*. 11(5):633-646. doi: 10.1517/17425247.2014.889678. Epub 2014 Mar 7.PMID: 24606222
43. S Kansal, R Tandon, A Verma, P Misra, A Choudhary, R Verma, P Verma, **A Dube**, P Mishra (2014) Coating of doxorubicin loaded nanocapsule with alginate enhances its therapeutic efficacy through Th1 type immune response in *Leishmania donovani* infected hamsters. *Br J Pharmacol.* 171(17):4038-4050. doi: 10.1111/bph.12754. Epub 2014 Jul 25.PMID: 24837879
44. PK Gupta, S Asthana, AK Jaiswal, V Kumar, AK Verma, P Shukla, P Dwivedi, **A Dube**, PR Mishra (2014) Exploitation of lectinized lipo-polymerosome encapsulated amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis. *Bioconjug Chem*. 25 (6):1091-1102.  doi: 10.1021/bc500087h. Epub 2014 Jun 9.PMID: 24842628
45. R Tandon, S Chandra, RK Baharia, S Das, P Misra, A Kumar, MI Siddiqi, S Sundar, **A Dube** (2014) Characterization of Proliferating Cell Nuclear Antigen of *Leishmania donovani* clinical isolate and its association with antimony resistance. *Antimicrobial Agents and Chemotherapy* 58 (6):2997-3007.  doi: 10.1128/AAC.01847-13. Epub 2014 Mar 10.PMID: 24614385
46. CDP Tripathi, R Gupta, PK Kushawaha, C Mandal, S Misra-Bhattacharya, **A Dube** (2014) Efficacy of *Withania somnifera* chemotypes NMITLI - 101R, 118R and Withaferin A against experimental visceral leishmaniasis. *Parasite Immunol*. 36 (6):253-265. doi: 10.1111/ pim.12112.PMID: 24830833
47. PK Gupta, A Jaiswal, V Kumar, A Verma, P Dwivedi, **A Dube**, PR Mishra (2014) Covalent functionalized Self-assembled Lipo-polymerosome bearing Amphotericin B for better management of leishmaniasis and its toxicity evaluation. *Molecular Pharmaceutics* 11(3):951-963. doi: 10.1021/mp400603t. Epub 2014 Feb 19.PMID: 24495144
48. R Gupta, V Kumar, PK Kushawaha, CDP Tripathi, S Joshi, AA Sahasrabuddhe, K Mitra, S Sundar, MI Siddiqi, **A Dube** (2014) Characterization of glycolytic enzymes - rAldolase and rEnolase of *Leishmania donovani*, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis. *PLOS One* 9: e86073.  doi: 10.1371/journal.pone.0086073. eCollection 2014.PMID: 24475071
49. A Kumar, P Misra, B Sisodia, AK Shasany, S Sundar, **A Dube** (2014). Mass spectrometry-based proteomic analysis of *Leishmania donovani* soluble proteins in Indian clinical isolate. *Pathog Dis*. 70(1):84-87. doi: 10.1111/2049-632X.12103.PMID: 24115687
50. P Khare, A Jaiswal, CDP Tripathi, S Joshi, **A Dube** (2014) Efficacy of *Leishmania donovani* Trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis. *Parasitology Research* 113:851-62. doi: 10.1007/s00436-013-3716-5. Epub 2013 Dec 27.PMID: 24370734
51. R Tandon, P Misra, VK Soni, N Bano, S Misra-Bhattacharya, **A Dube** (2013). Unresponsiveness of *Mycobacterium w* vaccine in managing acute and chronic Leishmania donovani infections in mouse and hamster. *Parasitology*. 140: 435-444. doi: 10.1017/S0031182012001850. Epub 2012 Dec 20. PMID: 23253783
52. S Das, P Shah, RK Baharia, R Tandon, P Khare, S Sundar, AA Sahasrabuddhe, MI Siddiqi, **A Dube** (2013) Over-Expression of 60s Ribosomal L23a is associated with cellular proliferation in SAG resistant clinical isolates of *Leishmania donovani*. *PLOS Neglected Tropical Diseases* 7: e2527. doi: 10.1371/journal.pntd.0002527. eCollection 2013.PMID: 24340105
53. S Asthana, PK Kushawaha, M Chaurasia, **A Dube**, M Chourasia (2013) Polymeric Colloidal Particulate Systems: Intelligent Tools for Intracellular Targeting of Antileishmanial Cargos. *Expert Opinion on Drug Delivery* 10 :1633-1651. doi: 10.1517/17425247.2013.838216. Epub 2013 Oct 23.
54. S Kansal, R Tandon, PR Verma, **A Dube**, PR Mishra (2013) Development of Doxorubicin Loaded Novel Core Shell Structured Nanocapsules for the intervention of Visceral Leishmaniasis. *Journal of microencapsulation* 30 :441-450. doi: 10.3109/02652048.2012.752532. Epub 2013 Mar 27.PMID: 23534494
55. D Kumar, P Tiwary, **A Dube**, J Chakravarty, M Rai, S Sundar (2013) Cloning, Expression and Purification of L. donovani Specific Antigen for Serodiagnosis of Visceral Leishmaniasis. *Journal of Molecular Biomarkers & Diagnosis* 4: 141, PMID: [24795833](https://www.ncbi.nlm.nih.gov/pubmed/24795833)
56. S Asthana, A Jaiswal, P Gupta, V Pawar, **A Dube**, M Chourasia (2013) Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using Amphotericin B encapsulated nano-emulsion template-based chitosan nanocapsules. *Antimicrobial Agents and Chemotherapy* 57 (4):1714-1722. doi: 10.1128/AAC.01984-12. Epub 2013 Jan 28. PMID: 23357762
57. A Pal, S Gupta, A Jaiswal, **A Dube**, SP Vyas (2012) Development and Evaluation of Tripalmitin Emulsomes for the Treatment of Experimental Visceral Leishmaniasis". *J Liposome Res* 22: 62-71. doi: [10.3109/08982104.2011.592495](https://doi.org/10.3109/08982104.2011.592495); PMID: 21740098
58. D Singodia, A Verma, P Khare, **A Dube**, K Mitra, PR Mishra (2012) Investigations on feasibility of in situ development of amphotericin B liposomes for industrial applications. J *Liposome Res*. 22:8-17 doi: 10.3109/08982104.2011.584317. Epub 2011 Jun 20.PMID: 21682670.
59. PK Kushawaha, R Gupta, CDP Tripathi, P Khare, AK Jaiswal, S Sundar, **A Dube** (2012). *Leishmania donovani* Triose Phosphate Isomerase: a potential vaccine target against Visceral Leishmaniasis. *PLoS One*; 7: e45766 doi: 10.1371/journal.pone.0045766. Epub 2012 Sep 24. PMID: 23049855.
60. S Kansal, R Tandon, P Dwivedi, P Misra, PR Verma, **A Dube**, PR Mishra (2012) Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis. *Journal of Antimicrobial Chemotherapy* 67:2650-2660. doi: 10.1093/jac/dks286. Epub 2012 Aug 7. PMID: 22872448
61. R Gupta, P Kushawaha, A Sahasrabuddhe, S Sundar, **A Dube** (2012) A novel recombinant Leishmania donovani p45-a partial coding region of methionine aminopeptidase protein generates protective immunity by inducing Th1 stimulatory response against experimental visceral Leishmaniasis. *International Journal for Parasitology* 42 :429-435 doi: 10.1016/ j.ijpara.2012.02.013. Epub 2012 Mar 27. PMID: 22502587.
62. PK Kushawaha, R Gupta, CDP Tripathi, S Sundar, **A Dube** (2012) Evaluation of Leishmania donovani Protein disulfide isomerase as a potential immunogenic protein / vaccine candidate against visceral leishmaniasis. *PLoS One*; 7: e35670. doi: 10.1371/journal.pone.0035670. Epub 2012 Apr 23. PMID: 22539989
63. P Khare, AK Gupta, PK Gajula, KY Sunkari, AK Jaiswal, S Das, P Bajpai, TK Chakraborty, **A Dube**, AK Saxena (2012) Identification of Novel S-Adenosyl-L-Homocysteine Hydrolase inhibitors through Homology-Model-Based Virtual Screening, Synthesis and Biological evaluation. *Journal of Chemical Information and Modeling (J Chem Inf Model)* 52:777-791. doi: 10.1021/ci2005862. Epub 2012 Feb 27. PMID: 22324915
64. S Kumari, P Misra, R Tandon, M Samant, S Sundar, **A Dube** (2012) *Leishmania donovani*: Immunostimulatory Cellular Responses of Membrane and Soluble Protein Fractions of Splenic Amastigotes in Cured Patient and Hamsters. *PLoS One* 7:e30746. doi: 10.1371/ journal. pone.0030746. Epub 2012 Jan 26. PMID: 22292030
65. R Gupta, PK Kushawaha, M Samant, AK Jaiswal, RK Baharia, **A Dube** (2012) Treatment of Leishmania donovani infected Hamster with Miltefosine: Time dependent Analysis of mRNA cytokine expression by Real-Time PCR, Lymphoproliferation, Nitrite production and antibody responses. *J Antimicrob Chemother* 67:440-443. doi: 10.1093/jac/dkr485. Epub 2011 Nov 25. PMID: 22121191
66. D Singodia, P Khare, **A Dube**, S Talegaonkar, RK Khar, PR Mishra (2011) Development and performance evaluation of alginate-capped amphotericin B lipid nanoconstructs against visceral leishmaniasis. *J Biomed Nanotechnol*. 7:123-124. doi: 10.1166/jbn. 2011.1232.PMID: 21485834
67. PK Kushwaha, R Gupta, S Sundar, AA Sahasrabuddhe, **A Dube** (2011) Elongation Factor-2- a Th1 and IL-12 stimulatory protein of *Leishmania donovani* generates strong IFN-γ response in cured Leishmania-infected patients/hamsters and protects hamsters to Leishmania challenge. *J Immunol* 187:6417-6427.doi: 10.4049/jimmunol.1102081. Epub 2011 Nov 11. PMID: 22079980
68. P Singh, A Gupta, A Jaiswal, **A Dube**, S Mishra, MK Chaurasia (2011) Design and development of Amphotericin B bearing polycaprolactone microparticles for macrophage targeting. *J.Biomed Nanotechnol*. 7 (1):50-51. doi: 10.1166/jbn.2011.1196.PMID: 21485798
69. S Sharma, P Kumar, A Jaiswal, **A Dube**, S Gupta (2011) Development and characterization of doxorubicin loaded microparticles against experimental visceral leishmaniasis. *J Biomed Nanotechnol*. 7(1):135-136. doi: 10.1166/jbn.2011.1237.PMID: 21485839
70. S Kunjachan, S Gupta, AK Dwivedi, **A Dube**, MK Chourasia (2011) Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis. *J Microencapsul*. 28 :301-310. doi: [10.3109/02652048.2011.559281](https://doi.org/10.3109/02652048.2011.559281) PMID: 21545321
71. A Kumar, B Sisodia, P Misra, S Sundar, AK Shasany, **A Dube** (2010) Proteome mapping of overexpressed membrane-enriched/cytosolic-proteins in Sodium Antimony Gluconate resistant clinical isolate of *Leishmania donovani*. *British Journal of Clinical Pharmacology* 70 (4): 609–617. doi: 10.1111/j.1365-2125.2010.03716.x.PMID: 20840452
72. J Kaur, N Singh, BK Singh, **A Dube**, RP Tripathi, P Singh, N Singh (2010) *Leishmania donovani*: Oral therapy with glycosyl 1,4-dihydropyridine analogue showing apoptosis like phenotypes targeting pteridine reductase 1 in intracellular amastigotes. *Experimental Parasitology*. Jul; 125 (3):310-314. doi: 10.1016/j.exppara.2010.02.011. Epub 2010 Feb 26
73. D Singodia, GK Gupta, A Verma, V Singh, P Shukla, P Misra, S Sundar, **A Dube**, PR Mishra (2010) Development and Performance Evaluation of Amphotericin B Transfersomes against Resistant and Sensitive Clinical Isolates of Visceral Leishmaniasis. *Journal of Biomedical Nanotechnology* 6: 293-302.DOI: [10.1166/jbn.2010.1121](https://doi.org/10.1166/jbn.2010.1121) PMID: 21179947
74. P Misra, KV Sashidhara, SP Singh, A Kumar, R Gupta, S Srivastava, SS Gupta, HK Majumder, A K Saxena, **A Dube** (2010) 16α-hydroxycleroda-3, 13 (14) Z-dien-15, 16-olide from *Polyalthia longifolia*: A safe and orally active antileishmanial agent. *British Journal of Pharmacology* 159:1143-1150.  doi: 10.1111/j.1476-5381.2009.00609.x. Epub 2010 Feb 5.PMID: 20136832
75. M Nahar, V Dubey, D Mishra, PK Mishra, A Dube, NK Jain (2010) *In vitro* evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. *Journal of Drug Targeting* 18 :93-105.; doi: [10.3109/10611860903115290](https://doi.org/10.3109/10611860903115290) PMID: 19640212
76. A Kumar, VR Boggula, P Misra, S Sundar, AK Shasany, **A Dube** (2010) Amplified Fragment Length Polymorphism (AFLP) analysis is useful for distinguishing Leishmania species of visceral and cutaneous forms. *Acta Tropica*. 113 (2): 202-206. doi: 10.1016/ j.actatropica.2009.10.006. Epub 2009 Oct 23. PMID: 19854144
77. A Dangi, S Vedi, JK Nag, S Painthacker, MP Singh, SK Kar, **A Dube**, S Misra-Bhattacharya (2009) Tetracycline treatment targeting Wolbachia affects expression of an array of proteins in *Brugia malayi* parasite. *Proteomics* 9 (17):4192-4208. doi: [10.1002/pmic.200800324](https://doi.org/10.1002/pmic.200800324) PMID: 19722191
78. N Singh, J Kaur, P Kumar, S Gupta, N Singh, A Ghosal, A Dutta, A Kumar, RP Tripathi, MI Siddiqi, C Mandal, **A Dube** (2009) An orally effective dihydropyrimidone (DHPM) analogue induces apoptosis like cell death in clinical isolates of *Leishmania donovani* overexpressing pteridine reductase 1. *Parasitology Research* 105 (5):1317-1325. doi: 10.1007/s00436-009-1557-z. Epub 2009 Jul 21. PMID: 1962124
79. R Maurya, P Gupta, K Chand, N Singh, M Kumar, P Dixit, **A Dube** (2009) Constituents of *Tinospora sinensis* and their antileishmanial activity against *Leishmania donovani*. Natural Product Research 23, (12): 1134 -1143.
80. N Singh, R Gupta, AK Jaiswal, S Sundar, **A Dube** (2009) Transgenic *Leishmania donovani* clinical isolates expressing GFP-constitutively for rapid and reliable *ex-vivo* drug screening. *Journal of Antimicrobial Chemotherapy* 64(2):370-374. doi: 10.1093/jac/dkp206. Epub 2009 Jun 12. PMID: 19525291
81. M Samant, R Gupta, S Kumari, P Misra, P Khare, PK Kushawaha, AA Sahasrabuddhe, **A Dube** (2009) Immunization with the DNA encoding N terminal domain of Proteo-phosphoglycan3 of *Leishmania donovani* generates Th-1 type immuno-protective response against experimental visceral leishmaniasis. *Journal of Immunology* 183(1):470-479. doi: 10.4049/jimmunol.0900265.PMID: 19542458
82. P Misra, A Kumar, P Khare, N Kumar, **A Dube** (2009) A pro-apoptotic effect of Landrace of Piper betle- Bangla Mahoma on *Leishmania donovani* may be due to high content of eugenol. *Journal of Medical Microbiology* 58 (Pt 8):1058-1066. doi: 10.1099/jmm.0.009290-0. Epub 2009 Jun 15. PMID: 19528177
83. T Khaliq, P Misra, S Gupta, KP Reddy, R Kant, PR Maulik, **A Dube**, T Narender (2009) Peganine hydrochloride dihydrate an orally active antilesihmanial agent. *Bioorganic & Medicinal Chemistry Letters* **19**(9):2585-2586. doi: 10.1016/j.bmcl.2009.03.039. Epub 2009 Mar 16. PMID: 19339182
84. GK Gupta, S Kansal, P Misra, **A Dube**, PR Mishra (2009) Uptake of biodegradable gel-assisted LBL nanomatrix by *Leishmania donovani*-infected macrophages. *AAPS PharmSciTech*. **10** (4):1343-1347. doi: 10.1208/s12249-009-9334-y. Epub 2009 Nov 11. PMID: 19904614
85. A Kumar, VR Boggula, S Sundar, AK Shasany, **A Dube** (2009) Identification of genetic markers in SAG sensitive and resistant Indian clinical isolates of *Leishmania donovani* through amplified fragment length polymorphism (AFLP). *Acta Tropica* **110**: 80–85. doi: 10.1016/ j.actatropica.2009.01.005.PMID: 19283900
86. S Kumari, M Samant, P Khare, P Misra, S Dutta, BK Kolli, S Sharma, KP Chang, **A Dube** (2009) Photodynamic vaccination of hamsters with inducible suicidal mutants of *Leishmania amazonensis* elicits T cell-transferable immunity against visceral leishmaniasis. *European Journal of Immunology* **39** (1):178-191. doi: 10.1002/eji.200838389.PMID: 19053149
87. P Tripathi, SK Gupta, S Sinha, S Sundar, **A Dube**, S Naik (2008) Prophylactic efficacy of high molecular weight antigenic fractions of a recent clinical isolate of *L. donovani* against Visceral Leishmaniasis. *Scandinavian Journal of Immunology* **68** (5):492-501. doi: 10.1111/j.1365-3083.2008.02171.x. Epub 2008 Sep 18.PMID: 18803606
88. P Misra, T Khaliq, A Dixit, S Sengupta, M Samant, S Kumari, A Kumar, P Kushawaha, H Majumder, AK Saxena, T Narender, **A Dube** (2008) Antileishmanial activity mediated by apoptosis and structure-based target study of Peganine hydrochloride dihydrate: An approach for rational drug designing. *Journal of Antimicrobial Chemotherapy* **62** (5):998-1002. doi: 10.1093/jac/dkn319. Epub 2008 Aug 11. PMID: 18694906
89. S Kumari, M Samant, P Misra, P Khare, B Sisodia, AK Shasany, **A Dube** (2008) Th1-stimulatory polyproteins of soluble *Leishmania donovani* promastigotes ranging from 89.9 to 97.1kDa offers long-lasting protection against experimental visceral leishmaniasis. *Vaccine*. 26 (45):5700-5711. doi: 10.1016/j.vaccine.2008.08.021. Epub 2008 Aug 30.PMID: 18762224
90. S Kumari, M Samant, P Khare, S Sundar, S Sinha, **A Dube** (2008) Induction of Th1-type cellular responses in cured/exposed Leishmania infected patients and hamsters against poly proteins of soluble *Leishmania donovani* promastigotes ranging from 89.9-97.1 kDa. *Vaccine* 26 (37):4813-4818. doi: 10.1016/j.vaccine.2008.06.102. Epub 2008 Jul 24.PMID: 18656517
91. P Kumar, A Kumar, SS Verma, N Dwivedi, N Singh, MI Siddiqi, RP Tripathi, **A Dube**, N Singh (2008) *Leishmania donovani* pteridine reductase 1: Biochemical properties and structure-modelling studies. *Experimental Parasitology* 120 (1):73-79. doi: 10.1016/j.exppara .2008.05.005. Epub 2008 Jun 2.PMID: 18617167
92. KD Manandhar, TP Yadav, VK Prajapati, S Kumar, M Rai, **A Dube**, ON Srivastava, S Sundar (2008) Antileishmanial activity of nano-amphotericin B deoxycholate. *Journal of Antimicrobial Chemotherapy*; 62 (2):376-380. doi: 10.1093/jac/dkn189. Epub 2008 May 2. PMID: 18453526
93. N Singh, R Kumar, S Gupta, **A Dube**, V Lakshmi (2008) Antileishmanial activity *in vitro* and *in vivo* of constituents of sea cucumber *Actinopyga lecanora*. *Parasitology Research*. Jul; 103(2):351-354. doi: 10.1007/s00436-008-0979-3. Epub 2008 May 2. PMID: 18452039.
94. N Singh, A Kumar, P Gupta, K Chand, M Samant, R Maurya, **A Dube** (2008) Evaluation of antileishmanial potential of *Tinospora sinensis* against experimental visceral leishmaniasis. *Parasitology Research*. Feb; 102 (3):561-565. doi: 10.1007/s00436-007-0822-2. Epub 2007 Dec 13.PMID: 18080140
95. N Singh, M Samant, SK Gupta, A Kumar, **A Dube** (2007) Age-influenced population kinetics and immunological responses of *Leishmania donovani* in hamsters. *Parasitology Research* 101(4):919-924. doi: 10.1007/s00436-007-0562-3. Epub 2007 May 7. PMID: 17484071
96. M Samant, AA Sahasrabuddhe, N Singh, SK Gupta, S Sundar, **A Dube** (2007) Proteophosphoglycan is differentially expressed in Sodium stibogluconate sensitive and resistant Indian clinical isolates of *Leishmania donovani*. *Parasitology* 134 (Pt 9):1175-1184. doi: 10.1017/S0031182007002569. Epub 2007 Mar 16 .PMID: 17362540
97. S Gupta, **A Dube**, SP Vyas (2007) Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. *Journal of Drug Targeting* 15(6):437-444. doi: 10.1080/10611860701453836.PMID: 17613662
98. **A Dube**, N Singh, A Saxena, V Lakshmi (2007) Antileishmanial potential of a marine sponge, Haliclona exigua (Kirkpatrick) against experimental visceral leishmaniasis. *Parasitology Research* 101(2):317-324. doi: 10.1007/s00436-007-0469-z. Epub 2007 Feb 10.PMID: 17294216
99. SK Gupta, BS Sisodia, S Sinha, K Hajela, S Naik, AK Shasany, **A Dube** (2007) Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of *Leishmania donovani* promastigotes. *Proteomics* 7: 816–823. doi: 10.1002/pmic.200600725.PMID: 17295358
100. V Lakshmi, K Pandey, A Kapil, N Singh, M Samant, **A Dube** (2007) *In vitro* and *in vivo* leishmanicidal activity of *Dysoxylum binectariferum* and its fractions against *Leishmania donovani*. *Phytomedicine* 14: 36–42. doi: 10.1016/j.phymed.2005.10.002. Epub 2005 Nov 15.PMID: 17190644
101. S Tewari, N Singh, S Shakya, A Dangi, S Misra-Bhattacharya, **A Dube**, N Kumar (2006) Landrace/gender-based differences in phenol and thiocyanate contents and biological activity in *Piper betle L*. *Current Science* 91: 746-749.
102. P Tripathi, S Ray, S Sundar, **A Dube**, S Naik (2006) Identification of *Leishmania donovani* antigens stimulating cellular immune responses in exposed immune individuals. *Clinical and Experimental Immunology* 143: 380-388. doi: 10.1111/j.1365-2249.2005. 03000.x.PMID: 16412064
103. A Hasan, M Satyanarayana, A Mishra, DS Bhakuni, R Pratap, **A Dube**, PY Guru (2006) Acyclic pyrazolo [3,4-d] pyrimidine nucleoside as potential leishmaniostatic agent. *Nucleosides, Nucleotides & Nucleic Acids* 25: 55-60. doi: 10.1081/ 15257770500379017.PMID: 16440985
104. R Garg, SK Gupta, P Tripathi, K Hajela, S Sundar, S Naik, **A Dube** (2006) *Leishmania donovani*: Identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. *Vaccine* 24: 2900-2909. doi: 10.1016/j.vaccine.2005.12.053. Epub 2006 Jan 17.PMID: 16448729
105. SK Sharma, **A Dube**, N Ahmad, S Khan, I Saleem, R Garg, M Owais (2006) Non-PC liposome entrapped promastigote antigens elicit parasite specific CD8 + and CD4 + T-cell immune response and protect hamsters against visceral leishmaniasis. *Vaccine* 24:1800–1810. doi: 10.1016/j.vaccine.2005.10.025. Epub 2005 Oct 28.PMID: 16310900
106. PK Mishra, N Singh, G Ahmad, **A Dube**, R Maurya (2005) Glycolipids and other constituents from *Desmodium gangeticum* with antileishmanial and immunomodulatory activity. *Bioorganic and Medicinal Chemistry Letters* 15: 4543-4546. doi: 10.1016/j.bmcl. 2005.07.020.PMID: 16099649
107. N Singh, PK Mishra, A Kapil, KR Arya, R Maurya, **A Dube** (2005) Efficacy of *Desmodium gangeticum* extract and its fractions against experimental visceral leishmaniasis. *Journal of Ethnopharmacology*, 98: 83–88.  doi: 10.1016/j.jep.2004.12.032.PMID: 15763367
108. R Garg, SK Gupta, P Tripathi, S Naik, S Sundar, **A Dube** (2005) Immunostimulatory cellular responses of cured Leishmania infected patients and hamsters against the Integral Membrane Proteins and Non-Membranous Soluble Proteins of recent clinical isolate of *Leishmania donovani*. *Clinical and Experimental Immunology* 140: 149-156. doi: 10.1111/j.1365-2249.2005.02745.x.PMID: 15762886
109. R Garg, JK Srivastava, A Pal, S Naik, **A Dube** (2005) Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis. *Vaccine* 23:1189-1196. doi: 10.1016/j. vaccine.2004.06.054. PMID: 15629362
110. **A Dube**, N Singh, S Sundar, N Singh (2005) Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persists in *in vitro* and *in vivo* experimental models. *Parasitology Research* 96: 216-223. doi: 10.1007/s00436-005-1339-1. Epub 2005 May 3.PMID: 15868188
111. A Misra, **A Dube**, S Naik (2004) Immune Responses in normal Indian langurs (Presbytis entellus) - A Primate Model for Visceral Leishmaniasis. *Journal of Medical Primatology* 68 (2): 1-3. doi: [10.1111/j.1600-0684.2004.00045.x](https://doi.org/10.1111/j.1600-0684.2004.00045.x) PMID: 15061718
112. N Singh, **A Dube** (2004) Fluorescent Leishmania: Applications to antileishmanial drug testing. *American Journal of Tropical Medicine and Hygiene* 71 (4): 400-402. PMID: 15516633
113. R Garg, N Singh, **A Dube** (2004) Intake of nutrient supplements affects population kinetics of Leishmania donovani in hamsters. *Parasitology* 129 (6): 685-691. doi: 10.1017/s0031182004006055.PMID: 15648691
114. P Sharma, N Singh, R Garg, W Haq, **A Dube** (2004) Efficacy of human B-casein fragment (54-59) and its synthetic analogue compound 89/215 against Leishmania donovani in hamsters. *Peptides* 25:1873–1881. doi: 10.1016/j.peptides.2004.06.011.PMID: 15501518
115. JK Srivastava, A Misra, P Sharma, B Srivastava, S Naik, **A Dube** (2003) Prophylactic Potential of Autoclaved *Leishmania donovani* with BCG against Experimental Visceral Leishmaniasis. *Parasitology* 127 (12): 107-114. doi: 10.1017/s0031182003003457.PMID: 12954011
116. P Sharma, S Rastogi, S Bhatnagar, JK Srivastava, **A Dube**, PY Guru, DK Kulshreshtha, BN Dhawan (2003) Antileishmanial action of a plant *Tephrosia purpurea* and its fractions against experimental Visceral Leishmaniasis. *Drug Development Research* 60 (4): 285-293.<https://doi.org/10.1002/ddr.10324>
117. A Misra, **A Dube**, JK Srivastava, P Sharma, JC Katiyar, S Naik (2002) Establishment of asymptomatic *Leishmania donovani* infection in Indian langurs (*Presbytis entellus*) through natural route. *Indian Journal of Experimental Biology* 40 (5): 605-608. PMID: 12622211
118. NL Pal, **A Dube** (2002) Ultrastructural Organization of the nucleus of the amastigotes of Leishmania donovani. *Advances in Biosciences* 21 (1): 53-58.
119. A Misra, **A Dube**, B Srivastava, P Sharma, JK Srivastava, JC Katiyar, S Naik (2001) Successful vaccination against Leishmania donovani infection in Indian langur using Alum-precipitated Autoclaved L. major (ALM) with BCG. *Vaccine* 19 (25-26): 3485-3492. doi: 10.1016/s0264-410x(01)00058-5.PMID: 11348715
120. NL Pal, P Sharma, **Anuradha** (2000) An improved Method for staining leishmanial amastigotes using Geimsa’s stain. *Journal of Parasitic Diseas*es 24 (2): 203-204.
121. P Sharma, **Anuradha**, A Rohatgi, W Haq, KB Mathur, JC Katiyar (1999) Stimulation of non-specific resistance by thymopentin and its analgos against *Leishmania donovani* infection in hamsters. *Peptides* 20 (11): 1381-1383. doi: 10.1016/s0196-9781(99)00146-1.PMID: 10612455
122. **Anuradha**, JK Srivastava, P Sharma, A Chaturvedi, JC Katiyar, S Naik (1999) *Leishmania donovani*: Cellular and humoral immune responses in Indian langur monkey *Presbytis entellus. Acta Tropica* 73:37-48. doi: 10.1016/s0001-706x(99)00007-8.PMID: 10379815
123. P Sharma, SP Singh, **Anuradha**, HP Gupta, JC Katiyar, VML Srivastava (1998) Vaccination with *Mycobacterium habana*: Impact on macrophage effector system during Leishmania donovani infection in hamsters. *Journal of Parasitic Diseases* 22: 100-103.
124. P Sharma, **Anuradha**, JK Srivastava, HP Gupta, JC Katiyar (1998) Immunization against Leishmania donovani: Efficacy of *Mycobacterium habana* in combination with killed promastigotes in hamsters. *Current Science* 74 (9): 770-773.
125. **A Dube**, P Sharma, JK Srivastava, A Misra, S Naik, JC Katiyar (1998) Vaccination of langur monkeys (*Presbytis entellus*) against *Leishmania donovani* with autoclaved *L. major* plus BCG. *Parasitology* 116: 219-221. doi: 10.1017/s0031182097002175.PMID: 9550214
126. P Sharma, **Anuradha**, R Sharan, W Haq, B Kundu, JC Katiyar, KB Mathur (1996) Stimulation of non-specific resistance by human casein fragment (54-59) and its synthetic analogues against Leishmania donovani infection. *Protein and Peptide letters* 3 (4): 261-266.
127. K Zehra, R Pal, **Anuradha**, SY Rizvi, W Haq, B Kundu, JC Katiyar, KB Mathur (1995) *Leishmania donovani* in hamsters: stimulation of non-specific resistance by novel lipopeptides and their effect in antileishmanial therapy. *Experientia* 51: 725-730. doi: 10.1007/BF01941270.PMID: 7628580
128. **Anuradha**, K Zehra, JC Katiyar, HP Gupta, NB Singh (1995) Vaccination of hamster with *Mycobacterium habana* against *Leishmania donovani*. *Current Science* 68 (1): 90-92.
129. **Anuradha**, R Pal, K Zehra, JC Katiyar, N Sethi, G Bhatia, RK Singh (1992) The Indian langur: preliminary report of a new non-human primate host for visceral leishmaniasis. *Bulletin of World Health Organization* 70: 63-72. PMID: 1314709
130. VC Pandey, **A Misra**, A Agarwal, S Ghatak, JC Katiyar (1991) Hydrolases of preparasitic and parasitic stages of *Ancylostoma ceylanicum* and *Nippostrongylus brasiliensis* - a comparative study. *Helminthologia* 28: 37-39.
131. R Pal, **Anuradha**, SY Rizvi, B Kundu, KB Mathur, JC Katiyar (1991) *Leishmania donovani* in hamsters: Stimulation of non-specific resistance by some novel glycopeptides and their impact on therapeutic efficacy. *Experientia* 15: 486-490. doi: 10.1007/BF01959951.PMID: 2044704
132. **A Misra**, AK Srivastava, JC Katiyar, S Ghatak (1990) Effect of thiabendazole and mebendazole in in vitro metabolism of *Nippostrongylus brasiliensis* adults. *Indian Journal of Medical Research* 90: 56-58. PMID: 2345031
133. R Pal, **Anuradha**, PY Guru, JC Katiyar (1990) Impact of seasonal variation on *Leishmania donovani* in hamsters. *Indian Journal of Medical Research* 90: 59-62. PMID: 2345032
134. **Anuradha**, R Pal, JC Katiyar (1990) Sex-influenced population kinetics of *Leishmania donovani* in hamsters. *Indian Journal of Experimental Biology* 28: 876-879. PMID: 2279782
135. **Anuradha**, R Pal, PY Guru, JC Katiyar, N Sethi (1990) Successful transmission of *Leishmania donovani* in langurs (*Presbytis entellus*). *Current Science* 59 (12): 612-615.
136. **A Misra**, AK Srivastava (1990) Effect of thiabendazole and mebendazole on certain biochemical parameters of *Nippostrongylus brasiliensis* infected albino rat. *Indian Journal of Parasitology* 14 (2): 25-127.
137. A Hasan, RP Tripathi, R Pratap, DS Bhakuni, R Pal, **A Misra**, PY Guru, JC Katiyar (1989) Studies on nucleosides: part XX-synthesis and antileishmanial activity 4,6-substituted pyrazolo [3,4-d] pyrimidine nucleosides. *Indian Journal of Chemistry* 28B: 403-409.
138. R Pal, **Anuradha**, PY Guru, JC Katiyar (1989) *Leishmania donovani* in hamster: Migration of amastigotes to unusual sites following drug therapy. *Medical Science Research* 17 (13): 579-581.
139. JC Katiyar, S Gupta, PKS Visen, PK Murthy, **A Misra**, S Kumar, JPS Sarin (1988) Methyl [5[4-(2-pyridinyl)-1-piperazinyl] carbonyl]-1H-benzimidazol-2-yl] carbamate efficacy against development and adult helminths by topical application. *Indian Journal of Experimental Biology* 26: 715-719.
140. LM Tripathi, BL Tekwani, S Mukerjee, A Agarwal, **A Misra**, VC Pandey, JC Katiyar, S Ghatak (1988) Hydrolytic enzymes during pathogenesis of *Nippostrongylus brasiliensis* infection in rats. *Indian Journal of Medical Research* 87: 225-228.
141. JK Srivastava, S Gupta, **A Misra**, JC Katiyar (1988) Chemo prophylactic action of a substituted methyl benzimidazole carbamate against experimental nematode infections. *Tropenmed Parasit* 39: 325-327. PMID: 3227236
142. S Mohan, NA Kaushal, **A Misra**, DC Kaushal, S Ghatak, JC Katiyar (1988) *Ancylostoma ceylanicum*: I Protein and antigenic composition of adult and larval stages. *Immunological Investigations* 17(4): 295-307. PMID: 3182019
143. **A Misra**, S Mohan, NK Kaushal, JC Katiyar, S Ghatak (1987) Antigenic analysis of larval and adult stages of *Ancylostoma ceylanicum* by immunoelectrophoretic techniques. *Indian Journal of Parasitology* 11 (1):21-22.
144. MM Khan, AK Srivastava, **A Misra**, JC Katiyar, S Ghatak (1987) Acid and alkaline hydrolases of jejunum of experimental animals during hookworm infection. *Revista de Parasitologia* Vol. IV (XLVIII) 125-129.
145. JC Katiyar, **A Misra**, S Gupta, PKS Visen, PK Murthy, AB Sen (1987) Efficacy of a substituted methyl benzimidazole carbamate aainst developing and adult helminth parasites. *Veterinary Parasitology* 23: 193-204. PMID: 3564348
146. BL Tekwani, LM Tripathi, S Mukherjee, **A Misra**, OP Shukla, SN Ghatak (1987) Impairment of hepatic microsomal drug metabolizing system in rats parasitized with *Nippostrongylus brasiliensis*. *Biochemical Pharmacology* 36 (8): 13893-1386.
147. **A Misra**, SK Misra, A Agarwal, JC Katiyar, SN Ghatak (1987) Effect of anthelmintics on the level of histamine in lungs and intestine of rats infected with *Nippostrongylus brasiliensis*. *Indian Journal of Medical Research* 85: 154-157.
148. PKS Visen, **A Misra**, JC Katiyar (1987) Speed of action of methyl 5(6)-4-2-pyridyl piperazino carbamoyl benzimidazole-2-carbamate (comp. 81-470), mebendazole and thiabendazole against *Nippostrongylus brasiliensis* and *Ancylostoma ceylanicum*. *Indian Journal of Experimental Biology* 25: 695-699. PMID: 3450592
149. A Misra, JC Katiyar (1986) Infectivity and longevity of *Nippostrongylus brasiliensis* infection in rats and *Mastomys natalensis*. *Indian Journal of Parasitology* 10 (1): 13-19.
150. JC Katiyar, *A Misra*, PKS Visen (1986) Role of host immunity on the efficacy of thiabendazole in rats infected with *Nippostrongylus brasiliensis*. *Wiadomosci Parazytologiczne*. *Parasitological news* TXXXII NR2: 163-167.
151. A Agarwal, *A Misra*, SK Misra, S Ghatak (1985) Monoamine oxidase in *Nippostrongylus brasiliensis*. *Indian Journal of Parasitology* 9(2):221-224.
152. JC Katiyar, PKS Visen, **A Misra**, S Gupta, AB Bhaduri (1984) Methyl 5(6)-4-2-pyridyl piperazino carbamoyl benzimidazole-2-carbamate-a new broad spectrum anthelmintic (Comp. 81-470). *Acta Tropica* 41: 279-286. PMID: 6150623
153. S Kumar, M Seth, AP Bhaduri, PKS Visen, **A Misra**, S Gupta, N Fatima, JC Katiyar, RK Chatterjee, AB Sen (1984) Synthesis and anthelmintic activity of alkyl 5(6)-N substitutes and N-N-disubstituted carbanyl benzimidazole-2-carbamate and related compounds. Journal of Medicinal Chemistry (USA) 27: 1083-1089. PMID: 6540312
154. S Abuzar, S Sharma, S Gupta, A Misra, JC Katiyar (1984) Synthesis and anthelmintic activity of 2-substitted 5(6)-(5-benzimidazolyl) and phenyl benzimidazoles. *Indian Journal of Chemistry* 23B: 1274-1278.
155. SK Agarwal, **A Misra**, JC Katiyar, S Ghatak (1983) Effect of levamisole on biogenic amines of *Nippostrongylus brasiliensis*. *Indian Journal of Medical Research* 78: 651-655.
156. **A Misra**, PKS Visen, JC Katiyar (1981) Comparative efficacy of standard antihookworm drugs against various test nematodes. *Journal of Helminthology* 55(4): 273-279. PMID: 7310109
157. **A Misra**, JC Katiyar (1980) Effect of temperature on survival and infectivity of larvae of *Nippostrongylus brasiliensis* and *Nematospiroides dubius*. *Indian Journal of Parasitology* 4: 195-198.
158. **A Misra**, JC Katiyar, AB Sen (1980) Experimental studies with *Nipppstrongylus brasiliensis* on factors modifying therapeutic efficacy of anthelmintics in rat. *Indian Journal of Experimental Biology* 18 (8): 906-909.

**Books/Chapters : Two**

1. Contributed a chapter related to “Syrian rue: *Peganum harmala* seeds and use in pharmacology” entitled “Harmala Seeds: Therapeutic Potential of Harmala ( *Peganum Harmala* L) Seeds with Array of Pharmacological Activities” In V. R. Preedy, R. R. Watson, V. B. Patel (Editors), Nuts & Seeds in Health and Disease Prevention (1st ed.) (pp 601-609). London, Burlington, San Diego: Academic Press is an imprint of Elsevier. ISBN: 9780123756886
2. Contributed in a book “Overview of Leishmaniasis with Special Emphasis on Kala-azar in South Asia Kwang Poo Chang, Bala K. Kolli and Collaborators © Springer International Publishing AG 2018 S.K. Singh (ed.), Neglected Tropical Diseases - South Asia, Neglected Tropical Diseases, https://doi.org/10.1007/978-3-319-68493-2\_1

**Reviews – 25**

1. M Anas, V Kumari, N Gupta, **A Dube**, N Kumar (2019). Protein quality control machinery in intracellular protozoan parasites: hopes and challenges for therapeutic targeting. *Cell Stress Chaperones*. 2019 Sep;24(5):891-904. doi: 10.1007/s12192-019-01016-9. Epub 2019 Jun 21.PMID: 31228085
2. S Ratnapriya, Keerti, AA Sahasrabuddhe, **A Dube (2019)**. Visceral leishmaniasis: An overview of vaccine adjuvants and their applications. *Vaccine.* 2019 Jun 12;37(27):3505-3519.
3. K Rawat, NK Yadav, S Joshi, S Ratnapriya, AA Sahasrabuddhe, **A Dube (2016)**. Management of visceral leishmaniasis with therapeutic vaccines. *Vaccine: Development and Therapy* 2016:6 1–13.
4. N Singh, **A Dube** (2015). Reporter Genes in Parasites. Encyclopaedia of Parasitology, H. Mehlhorn (ed.), # Springer-Verlag Berlin Heidelberg doi 10.1007/978-3-642-27769-6-3511-1.
5. S Joshi, K Rawat, NK Yadav, V Kumar, MI Siddiqi and **A Dube** (2014). Visceral leishmaniasis: advancements in vaccine development via classical and molecular approaches. *Immunotherapies and Vaccines*. *Frontiers in Immunology* August 22;5: 380.
6. A Kumar, P Misra, **A Dube** (2012) [Amplified fragment length polymorphism: an adept technique for genome mapping, genetic differentiation, and intraspecific variation in protozoan parasites.](http://www.ncbi.nlm.nih.gov/pubmed/23254590) *Parasitology Research* Feb;112 (2):457-66. doi: 10.1007/s00436-012-3238-6. Epub 2012 Dec 20. PMID: 23254590
7. N Kumar, S Gupta, **A Dube,** SP Vyas (2010). Emerging role of vesicular carriers for therapy of visceral leishmaniasis: conventional vs novel. *Critical reviews therapeutic drug carrier systems* **27**(6):461-507.
8. N Kumar, P Misra, M Dikshit, S Misra-Bhattacharya, **A Dube,** SA Ranade (2010). *Piper betle* (Betel Vine), a maligned plant of Pan-Asian culture with an array of pharmacological activities: A brighter perspective for drug discovery. *Current Science*. 99, 10 October (7):922-932
9. **A Dube**, R Gupta, N Singh **(2009)**. Reporter genes facilitating discovery of drugs targeting protozoan parasites. *Trends in Parasitology* Sep; 25 (9): 432-9. doi: 10.1080/ 14786410802682239.PMID: 19662579
10. S Kumari, A Kumar, M Samant, N Singh, **A Dube** (2008) Discovery of Novel Vaccine Candidates and Drug Targets against Visceral Leishmaniasis using Proteomics and Transcriptomics. *Current Drug Targets (Invited Review)* Nov; 9 (11): 938-47 doi: 10.2174/138945008786786091.PMID: 18991606
11. S Kumari, A Kumar, M Samant, S Sundar, N Singh, **A Dube** (2008). Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis. *Proteomics - Clinical Applications (invited review)* 2, 372–386 doi: 10.1002/prca.200780017. Epub 2008 Feb 13. PMID: 21136840
12. R Garg, **A Dube** **(2006).** Animal models for vaccine studies for visceral leishmaniasis. *Indian Journal of Medical Research* 123: 439-454. PMID: 16778322
13. **A Dube,** N Singh **(2005).** Experimental models for Kala azar vaccine and drug development research.*In* (Raghunath D, Nayak R, Eds). *Trends and Research in Leishmaniasis with particular reference to Kala Azar.* Tata McGraw-Hill Publishing Company Ltd., New Delhi. pp. 193-214.
14. **A Dube**, PK Murthy, SK Puri, S Misra-Bhattacharya (2004) *Presbytis entellus*: A Primate Model for Parasitic Disease Research. *Trends in Parasitology* 20 (8): 358-360. doi: 10.1016 /j.pt.2004.05.008.PMID: 15246317
15. **A** **Dube,** B Srivastava (2002) Kala-azar: The immunological consequences and feasibility of vaccination. *Journal of Immunology and Immunopathology* **4,** (1&2)Dec**:** 122-135.
16. JC Katiyar , **Anuradha** (1998) Possibilities and complexities in vaccination against kala-azar. *Proceedings of National Academy of Sciences* **LXVI**, Sec B, Pt II, 97-111. (Invited article)
17. JC Katiyar, **Anuradha** (1996) Visceral leishmaniasis: Approaches to experimental chemotherapy. *Proceedings of International Symposium on Leishmaniasis* BHU, Varanasi. March 24-25, 1996 (Ed. S. Sundar) pp 153-161.
18. JC Katiyar, **Anuradha,** Suman Gupta (1996). Parasite, Parasitism and Parasitosis. *DEI Journal of Scientific and Engineering Research.* **9**(142) 2-12.
19. JC Katiyar, **Anuradha** (1994). Leishmaniasis: a curse of poverty. In *Cultivation of Parasites*. Eds: JC Katiyar, NB Singh & VML Srivastava. Central Drug Research Institute, Lucknow. pp. 107-114.
20. PY Guru, **Anuradha** (1994) Cultivation and Experimental models of Leishmaniasis. In Cultivation of Parasites. Eds: JC Katiyar, NB Singh & VML Srivastava. Central Drug Research Institute, Lucknow. pp. 115-129.
21. JC Katiyar **Anuradha,** S Sharma (1992). Kala-azar: Current status of experimental chemotherapy.  *Medicinal Research Reviews* **12** (5) 473-504.
22. JC Katiyar, **Anuradha**, S Sharma (1991) Kala-azar: Current trends in chemotherapy. *Indian Review of Life Sciences* **11**, 79-94.
23. JC Katiyar, **Anuradha** (1989) Immunopharmacology of worm expulsion. *Journal of Scientific and Industrial Research* **48** (Jan) 15-21.
24. **Anuradha,** JC Katiyar (1987) Pharmacologically active cells and their regulatory function in helminthic infection. *Indian Journal of Parasitology* **11**(2): 103-116.
25. **A Misra,** JC Katiyar (1984) Avermectins-novel and unique broad-spectrum antiparasitic agents. *Journal of Scientific Industrial Research* **43**: 276-283.